Article
Dexmedetomidine sublingual film for agitation
Approved by the FDA on April 5, 2022, dexmedetomidine sublingual film (Igalmi, manufactured and distributed by BioXcel Therapeutics, Inc., New...
Article
Evidence-based medicine: It’s not a cookbook!
It’s not just about the evidence, it’s about how we use it in clinical practice.
Article
Asenapine transdermal system for schizophrenia
Approved by the FDA on October 11, 2019, asenapine transdermal system (Secuado, manufactured by Hisamitsu Pharmaceutical Co., Inc. and distributed...
Article
Aripiprazole, brexpiprazole, and cariprazine: Not all the same
Understanding the key differences among these agents can help inform treatment decisions.
Audio
Aripiprazole, brexpiprazole, and cariprazine
Leslie Citrome, MD, MPH, discusses the differences among 3 dopamine receptor partial agonists.
News
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder
Brexpiprazole, FDA-approved in July 2015 to treat schizophrenia and as an adjunct for major depressive disorder (MDD), has shown efficacy in 2...
News
Inhaled loxapine for agitation
Reformulation allows for direct administration to the lungs, resulting in rapid absorption into systemic circulation
Audio
How to best help patients with residual schizophrenia symptoms
Leslie Citrome, MD, MPH
News
Treatment-resistant schizophrenia: What can we do about it?
Use pharmacotherapy and other interventions to target the symptoms that matter most to your patient
Audio
When clozapine may be right for your patient, and how to initiate therapy
Leslie Citrome, MD, MPH
News
Clozapine for schizophrenia: Life-threatening or life-saving treatment?
Clozapine, despite its side effect burden, may be the most effective and have the lowest mortality risk among all available antipsychotics
News
Can you interpret confidence intervals? It’s not that difficult
NNT—medicine’s ‘secret stat’—offers infinite possibilities for clinical practice.
News
Dissecting clinical trials with ‘number needed to treat’
Calculation suggests a study’s value to your patients.
News
Antipsychotics for patients without psychosis?
What clinical trials support
News
Treatment-resistant schizophrenia: What role for mood stabilizers?
One-half of all seriously and persistently ill patients with schizophrenia may receive add-on lithium or anticonvulsants. Does the evidence...